Intravitreal corticosteroid approved

Article

Trivaris (triamcinolone acetonide injectable suspension; Allergan), a synthetic glucocorticoid corticosteroid, has been approved by the FDA for the treatment of inflammatory ophthalmic conditions.

Trivaris (triamcinolone acetonide injectable suspension; Allergan), a synthetic glucocorticoid corticosteroid, has been approved by the FDA for the treatment of inflammatory ophthalmic conditions.

Trivaris 80 mg/mL has been indicated for sympathetic ophthalmia, temporal arteritis, uveitis and other conditions unresponsive to treatment with topical corticosteroids.

Recent Videos
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
A digital map of the world, overlaid on top of a photo of a person writing with a pen in a notebook. Image credit: ©Pixels Hunter – stock.adobe.com

Arctic Vision partners with Santen Pharmaceutical Co., Ltd. to commercialise ARVN001 in China

Sydney M Crago
November 22nd 2024
Article

ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A syringe against a multicolor background, with a drip of liquid at the end of the needle. Image credit: ©iloli – stock.adobe.com

European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis

Sydney M Crago
November 20th 2024
Article

OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The FDA logo on a laptop computer. Image credit: ©monticellllo – stock.adobe.com

US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)

Hattie Hayes;Jordana Joy
November 19th 2024
Article

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

A phone and a computer with the NHS website pulled up. The webpage on the phone says "NHS Services." Image credit: ©Timon – stock.adobe.com

NHS introduces OCT programme to reduce annual hospital visits for patients with diabetes

Hattie Hayes
November 18th 2024
Article

Optical coherence tomography will be in all eye care services by October 2025

© 2024 MJH Life Sciences

All rights reserved.